Faster Detection of Malignant Thyroid Cancer
Point of care (POC) assay for the thyroid, allowing an instant answer on whether a tumor is DTC, so timely action can be taken
Differentiated thyroid carcinoma (DTC), which includes papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC), comprises the vast majority (>90%) of all thyroid cancers. Over the last 3 decades an increase in the incidence of DTC has been observed, mostly attributed to an increase in the incidence of PTC (2-3). It is expected that by 2030 DTC will become the fourth most common cancer in the general population and the second most common among women.
Inventors
Contact info
Avital Pritz, Director of Medical Devices and Digital Health
For further information please contact:
avital@mor-research.comTo develop a point of care (POC) assay for Tg which would, within minutes, provide an answer to a common clinical question: Does this lymph node represent a metastasis of differentiated thyroid carcinoma?
The Point-of-Care testing market was valued at $29.5 billion in 2020 and is expected to grow. Lateral Flow Assay alone was valued at $8.2 billion. Attempts to develop quantitative lateral flow assays are continuously being made by different groups around the world.
A multi center clinical study is in progress.